ClinicalTrials.gg
Active, not recruitingNCT06081829Updated Dec 9, 2025Results posted

A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

A Phase 2 interventional study of Ivosidenib in Cholangiocarcinoma Non-resectable and Cholangiocarcinoma Metastatic, sponsored by Servier. Active, not recruiting at 7 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Servier · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Cholangiocarcinoma with a site in Japan — 6 open to participants now, 14 under way, 3 of them phase 3. Cholangiocarcinoma · Japan.

Enrollment
26th of 28
12 · median 163
Started
2023
with 4 others
Phase 2
8 of 31
1 open now
Primary completion
2024-10
later than 2 of 13 live
Registered
22nd of 31
by date

Among the 31 studies in Cholangiocarcinoma with a site in Japan, this one is the 26th largest by enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2023, is one of 8 in phase 2, reaches primary completion later than 2 of the 13 other live ones, and was the 22nd registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

6 of the 31 studies in Cholangiocarcinoma with a site in Japan are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Cholangiocarcinoma with a site in Japan, or all of them as a file.
02

Study summary

This study will enroll participants with nonresectable or metastatic cholangiocarcinoma with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have previously received at least 1, but no more than 2, prior regimens for advanced disease. All participants will receive ivosidenib daily throughout multiple 28 day cycles. Study treatment will be administered until participant experiences unacceptable toxicity, disease progression, or other discontinuation criteria are met. Study visits will be conducted every week during Cycle 1 (Days 1, 8, 15, and 22), every other week during Cycles 2 and 3, and Day 1 of each cycle thereafter. After the last dose of treatment, participants will attend an end of treatment and a post-treatment follow-up visit, and participants will be followed to assess overall survival. Study visits may include a tumor assessment, physical exam, electrocardiogram (ECG), blood and urine analysis, and questionnaires.

03

Conditions studied

  • Cholangiocarcinoma Non-resectable
  • Cholangiocarcinoma Metastatic

Browse trials for

Keywords

  • IDH-1 Mutation
  • Cholangiocarcinoma Non-resectable with an IDH-1 Mutation
  • Cholangiocarcinoma Metastatic with an IDH-1 Mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have nonresectable or cholangiocarcinoma and are not eligible for curative resection, transplantation or ablative therapies
  • Have documented IDH1 gene-mutated disease from a tumor
  • Have an PS score of 0 or 1
  • Have an expected survival of 3 months or more
  • Have at least one evaluable and
  • Have disease progression following the most recent of 1 or 2 prior systemic regimens for advanced disease with progression on the treatment that was most recently given at a minimum, and must have received at least 1 gemcitabine- or 5-FU -containing regimen
  • Have recovered from side effects associated with the prior treatment therapy
  • Have adequate bone marrow function
  • Have adequate hepatic (liver) and renal (kidney) function
  • Women of child bearing potential must have a negative serum pregnancy test before starting study treatment, and use during the study and for 90 days after the last dose of ivosidenib
  • Fertile men with female partners of child bearing potential must use birth control during the study and for 90 days after the last dose of ivosidenib

Exclusion criteria

Exclusion Criteria:

  • Received a prior IDH inhibitor.
  • Have known symptomatic requiring .
  • Pregnancy, possibility of becoming pregnant during the study and breast-feeding women or woman who plans to restart breast-feeding after the study drug administration/intake.
  • Are taking known strong cytochrome P450 (CYP) 3A4 inducers or sensitive substrate medications with a narrow therapeutic window
  • Have significant heart disease, including congestive heart failure, myocardial infarction (heart attack) unstable angina (chest pain) and/or stroke, within 6 months before starting the study
  • Have a heart-rate interval ≥450 msec or other factors that increase the risk of QT prolongation or arrhythmic events
  • . Have active inflammatory gastrointestinal disease, chronic diarrhea, previous gastric resection or lap band dysphagia, short-gut syndrome, gastroparesis (paralysis of the stomach), or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.
  • Have known medical history of progressive multifocal leukoencephalopathy (PML)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Open-Label Ivosidenib

    250 mg Tablets

    Drug: Ivosidenib

Interventions

  • Subjects will take 2 tablets (500 mg total) orally once daily.

06

What researchers measure

Primary outcomes

  1. 6-month Progression Free Survival (PFS) Rate

    Proportion of subjects who are alive and progression-free (using RECIST v1.1) at 6 months after Day 1 (C1D1) per Independent Radiology Center (IRC)

    Time frame: Through 6 months after the first dose

Secondary outcomes

  1. Progression Free Survival (PFS)

    The time from Day 1 to the date of first documentation of disease progression as assessed by the Investigator and by the IRC per RECIST v1.1. or death due to any cause

    Time frame: Approximately 1 year

  2. Overall Survival (OS)

    Time frame: Approximately 1 year

  3. Objective Response (OR) Rate

    Complete response or partial response

    Time frame: Approximately 1 year

  4. Duration of Response (DOR)

    The time from date of first documented confirmed complete response (CR) or confirmed partial response (PR) to date of first documented disease progression or death due to any cause

    Time frame: Approximately 1 year

  5. Time to Response (TTR)

    The time from Day 1 to date of first documented confirmed complete response (CR) or confirmed partial response (PR)

    Time frame: Approximately 1 year

  6. Change From Baseline in Health-Related Quality of Life Using EORTC-QLQ-C30 Questionnaire Scores.

    The European Organisation for Research and Treatment of Cancer - Quality Of Life Questionnaire - Core Questionnaire (EORTC-QLQ-C30) is comprised of 5 functional scales ((Physical functioning, Role functioning, Cognitive functioning, Emotional functioning and Social functioning), 3 symptom scales (Fatigue, Pain and Nausea/Vomiting), 6 additional single items (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties) and global health status (GHS). All of the scale scores range from 0 - 100; for the functional scales and GHS the higher score represents better functioning and for the symptom scales and single items the higher score represents an increase in symptoms. .

    Time frame: Baseline and 1 year

  7. Change From Baseline in Health-Related Quality of Life Using EORTC-QLQ-BIL21 Questionnaire Scores.

    The European Organisation for Research and Treatment of Cancer - Quality Of Life Questionnaire - Cholangiocarcinoma and Gallbladder Cancer Module (EORTC-QLQ-BIL21) scores range from 0 - 100 with higher scores representing more severe symptoms.

    Time frame: Baseline and 1 year

  8. Average EQ-5D-5L VAS Scores

    The 5-level EuroQol five dimensions questionnaire (EQ-5D-5L) visual analogue scale (VAS) scores range from 0 to 100 with a higher number representing a better health status.

    Time frame: Baseline, Cycle 3 Day 1 (cycle = 28 days), and End of Treatment Visit (within 5 to 33 days after last dose of treatment, approximately 1 year total)

  9. Total Number of Adverse Events (AEs)

    Time frame: Approximately 1 year

  10. Total Number of Participants With Adverse Events (AEs) Leading to Dose Modifications

    Time frame: Approximately 1 year

  11. Total Number of Participants With Adverse Events (AEs) Leading to Discontinuation

    Time frame: Approximately 1 year

  12. Total Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Approximately 1 year

  13. Total Number of Participants With Adverse Events (AEs) Leading to Death

    Time frame: Approximately 1 year

  14. Average Area Under the Concentration-vs Time Curve From 0 to Time of Last Measurable Concentration (AUC0-t)

    Time frame: Cycle 1 Day 1 and Cycle 2 Day 1

  15. Average AUC Over 1 Dosing Interval at Steady State (AUCtau,ss)

    Time frame: Cycle 2 Day 1

  16. Average Time to Maximum Concentration (Tmax)

    Time frame: Cycle 1 Day 1 and Cycle 2 Day 1

  17. Average Maximum Concentration (Cmax)

    Time frame: Cycle 1 Day 1 and Cycle 2 Day 1

  18. Average Trough Concentration (Ctrough)

    Time frame: Cycle 2 Day 1

  19. Average Plasma 2-hydroxyglutarate (2-HG) Concentrations

    Time frame: Cycle 1 Day 1 and Cycle 2 Day 1

  20. Number of Participants With no Change, Plus 1 or Plus 2 Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status (ECOG PS) Score

    From baseline to worst value of post-baseline assessments. ECOG PS scores range from 0 to 5 with 0 representing a person being fully active and 5 being the patient is dead.

    Time frame: Approximately 1 year

07

Results

Posted Dec 9, 2025

Participant flow

Participant flow — Overall Study
MilestoneOpen-Label Ivosidenib
Started12
Completed0
Not completed12
Withdrew: Participants still on-study8
Withdrew: Death4

Outcome measures

Primary6-month Progression Free Survival (PFS) Rate

Proportion of subjects who are alive and progression-free (using RECIST v1.1) at 6 months after Day 1 (C1D1) per Independent Radiology Center (IRC)

Time frame:
Through 6 months after the first dose
Reported as:
Number · percentage of participants
6-month Progression Free Survival (PFS) Rate
percentage of participantsOpen-Label Ivosidenib
6-month Progression Free Survival (PFS) Rate25.0 (8.1 to 46.5)
SecondaryProgression Free Survival (PFS)

The time from Day 1 to the date of first documentation of disease progression as assessed by the Investigator and by the IRC per RECIST v1.1. or death due to any cause

Time frame:
Approximately 1 year
Reported as:
Median · months
Progression Free Survival (PFS)
monthsOpen-Label Ivosidenib
Progression Free Survival (PFS)4.21 (2.69 to NA)
SecondaryOverall Survival (OS)
Time frame:
Approximately 1 year
Reported as:
Median · months
Overall Survival (OS)
monthsOpen-Label Ivosidenib
Overall Survival (OS)NA (5.19 to NA)
SecondaryObjective Response (OR) Rate

Complete response or partial response

Time frame:
Approximately 1 year
Reported as:
Count of participants · Participants
Objective Response (OR) Rate
ParticipantsOpen-Label Ivosidenib
Objective Response (OR) Rate0
SecondaryDuration of Response (DOR)

The time from date of first documented confirmed complete response (CR) or confirmed partial response (PR) to date of first documented disease progression or death due to any cause

Time frame:
Approximately 1 year

No measurements were reported for this outcome.

SecondaryTime to Response (TTR)

The time from Day 1 to date of first documented confirmed complete response (CR) or confirmed partial response (PR)

Time frame:
Approximately 1 year

No measurements were reported for this outcome.

SecondaryChange From Baseline in Health-Related Quality of Life Using EORTC-QLQ-C30 Questionnaire Scores.

The European Organisation for Research and Treatment of Cancer - Quality Of Life Questionnaire - Core Questionnaire (EORTC-QLQ-C30) is comprised of 5 functional scales ((Physical functioning, Role functioning, Cognitive functioning, Emotional functioning and Social functioning), 3 symptom scales (Fatigue, Pain and Nausea/Vomiting), 6 additional single items (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties) and global health status (GHS). All of the scale scores range from 0 - 100; for the functional scales and GHS the higher score represents better functioning and for the symptom scales and single items the higher score represents an increase in symptoms. .

Time frame:
Baseline and 1 year
Reported as:
Mean · score on a scale
Change From Baseline in Health-Related Quality of Life Using EORTC-QLQ-C30 Questionnaire Scores.
score on a scaleOpen-Label Ivosidenib
Physical Functioning-6.7 ± 15.63
Role Functioning-9.3 ± 16.90
Cognitive Functioning-1.9 ± 10.02
Emotional Functioning-8.3 ± 18.63
Social Functioning-14.8 ± 17.57
Fatigue7.4 ± 16.67
Pain7.4 ± 32.39
Nausea/Vomiting7.4 ± 12.11
Dyspnea22.2 ± 40.82
Insomnia18.5 ± 29.40
Appetite Loss7.4 ± 32.39
Constipation-7.4 ± 14.70
Diarrhea3.7 ± 20.03
Financial Difficulties0.0 ± 23.57
GHS-20.4 ± 22.48
SecondaryChange From Baseline in Health-Related Quality of Life Using EORTC-QLQ-BIL21 Questionnaire Scores.

The European Organisation for Research and Treatment of Cancer - Quality Of Life Questionnaire - Cholangiocarcinoma and Gallbladder Cancer Module (EORTC-QLQ-BIL21) scores range from 0 - 100 with higher scores representing more severe symptoms.

Time frame:
Baseline and 1 year
Reported as:
Mean · score on a scale
Change From Baseline in Health-Related Quality of Life Using EORTC-QLQ-BIL21 Questionnaire Scores.
score on a scaleOpen-Label Ivosidenib
Change From Baseline in Health-Related Quality of Life Using EORTC-QLQ-BIL21 Questionnaire Scores.8.3 ± 12.50
SecondaryAverage EQ-5D-5L VAS Scores

The 5-level EuroQol five dimensions questionnaire (EQ-5D-5L) visual analogue scale (VAS) scores range from 0 to 100 with a higher number representing a better health status.

Time frame:
Baseline, Cycle 3 Day 1 (cycle = 28 days), and End of Treatment Visit (within 5 to 33 days after last dose of treatment, approximately 1 year total)
Reported as:
Mean · score on a scale
Average EQ-5D-5L VAS Scores
score on a scaleOpen-Label Ivosidenib
Baseline78.8 ± 10.80
Cycle 3 Day 175.8 ± 15.61
End of Treatment61.7 ± 27.05
SecondaryTotal Number of Adverse Events (AEs)
Time frame:
Approximately 1 year
Reported as:
Number · Number of Adverse Events
Total Number of Adverse Events (AEs)
Number of Adverse EventsOpen-Label Ivosidenib
Total Number of Adverse Events (AEs)24
SecondaryTotal Number of Participants With Adverse Events (AEs) Leading to Dose Modifications
Time frame:
Approximately 1 year
Reported as:
Count of participants · Participants
Total Number of Participants With Adverse Events (AEs) Leading to Dose Modifications
ParticipantsOpen-Label Ivosidenib
Total Number of Participants With Adverse Events (AEs) Leading to Dose Modifications0
SecondaryTotal Number of Participants With Adverse Events (AEs) Leading to Discontinuation
Time frame:
Approximately 1 year
Reported as:
Count of participants · Participants
Total Number of Participants With Adverse Events (AEs) Leading to Discontinuation
ParticipantsOpen-Label Ivosidenib
Total Number of Participants With Adverse Events (AEs) Leading to Discontinuation0
SecondaryTotal Number of Participants With Serious Adverse Events (SAEs)
Time frame:
Approximately 1 year
Reported as:
Count of participants · Participants
Total Number of Participants With Serious Adverse Events (SAEs)
ParticipantsOpen-Label Ivosidenib
Total Number of Participants With Serious Adverse Events (SAEs)2
SecondaryTotal Number of Participants With Adverse Events (AEs) Leading to Death
Time frame:
Approximately 1 year
Reported as:
Count of participants · Participants
Total Number of Participants With Adverse Events (AEs) Leading to Death
ParticipantsOpen-Label Ivosidenib
Total Number of Participants With Adverse Events (AEs) Leading to Death0
SecondaryAverage Area Under the Concentration-vs Time Curve From 0 to Time of Last Measurable Concentration (AUC0-t)
Time frame:
Cycle 1 Day 1 and Cycle 2 Day 1
Reported as:
Geometric mean · ng*h/mL
Average Area Under the Concentration-vs Time Curve From 0 to Time of Last Measurable Concentration (AUC0-t)
ng*h/mLOpen-Label Ivosidenib
Cycle 1 Day 118699 ± 43.5
Cycle 2 Day 122404 ± 27.4
SecondaryAverage AUC Over 1 Dosing Interval at Steady State (AUCtau,ss)
Time frame:
Cycle 2 Day 1
Reported as:
Geometric mean · ng*h/mL
Average AUC Over 1 Dosing Interval at Steady State (AUCtau,ss)
ng*h/mLOpen-Label Ivosidenib
Average AUC Over 1 Dosing Interval at Steady State (AUCtau,ss)74121 ± 30.0
SecondaryAverage Time to Maximum Concentration (Tmax)
Time frame:
Cycle 1 Day 1 and Cycle 2 Day 1
Reported as:
Median · hours
Average Time to Maximum Concentration (Tmax)
hoursOpen-Label Ivosidenib
Cycle 1 Day 12.98 (1.85 to 5.93)
Cycle 2 Day 13.83 (1.83 to 3.97)
SecondaryAverage Maximum Concentration (Cmax)
Time frame:
Cycle 1 Day 1 and Cycle 2 Day 1
Reported as:
Geometric mean · ng/mL
Average Maximum Concentration (Cmax)
ng/mLOpen-Label Ivosidenib
Cycle 1 Day 14918 ± 42.7
Cycle 2 Day 14781 ± 22.8
SecondaryAverage Trough Concentration (Ctrough)
Time frame:
Cycle 2 Day 1
Reported as:
Geometric mean · ng/mL
Average Trough Concentration (Ctrough)
ng/mLOpen-Label Ivosidenib
Average Trough Concentration (Ctrough)2058 ± 28.7
SecondaryAverage Plasma 2-hydroxyglutarate (2-HG) Concentrations
Time frame:
Cycle 1 Day 1 and Cycle 2 Day 1
Reported as:
Mean · ng/mL
Average Plasma 2-hydroxyglutarate (2-HG) Concentrations
ng/mLOpen-Label Ivosidenib
Cycle 1 Day 1597 ± 532.07
Cycle 2 Day 179.95 ± 41.166
SecondaryNumber of Participants With no Change, Plus 1 or Plus 2 Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status (ECOG PS) Score

From baseline to worst value of post-baseline assessments. ECOG PS scores range from 0 to 5 with 0 representing a person being fully active and 5 being the patient is dead.

Time frame:
Approximately 1 year
Reported as:
Count of participants · Participants
Number of Participants With no Change, Plus 1 or Plus 2 Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status (ECOG PS) Score
ParticipantsOpen-Label Ivosidenib
Baseline Score of 0 and Worst Post-Baseline Score of 0 (no change)7
Baseline Score of 0 and Worst Post-Baseline Score of 1 (+1 change)2
Baseline Score of 0 and Worst Post-Baseline Score of 2 (+2 change)1
Baseline Score of 1 and Worst Post-Baseline Score of 1 (no change)2

Adverse events

Collected over Approximately 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-Label Ivosidenib4/12 (33.3%)2/12 (16.7%)9/12 (75%)
Most frequent serious events
Most frequent serious events
EventOpen-Label Ivosidenib
Electrocardiogram QT prolongedInvestigations2/12
Most frequent other events
Showing 10 of 20
Most frequent other events
EventOpen-Label Ivosidenib
DiarrheaGastrointestinal disorders2/12
HypokalaemiaMetabolism and nutrition disorders2/12
Dry mouthGastrointestinal disorders1/12
DyspepsiaGastrointestinal disorders1/12
NauseaGastrointestinal disorders1/12
StomatitisGastrointestinal disorders1/12
VomitingGastrointestinal disorders1/12
FatigueGeneral disorders1/12
MalaiseGeneral disorders1/12
PyrexiaGeneral disorders1/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Open-Label Ivosidenib
Median61.5 ± 12.27
Age, Customized
Age, Customized(Participants)Open-Label Ivosidenib
45-<65 years old7
>=65 years old5
Sex: Female, Male
Sex: Female, Male(Participants)Open-Label Ivosidenib
Female5
Male7
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Open-Label Ivosidenib
Not Hispanic or Latino12
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Open-Label Ivosidenib
Asian12
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Open-Label Ivosidenib
Mean23.1 ± 4.39
08

Study locations

7 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After Marketing Authorization in EEA or US if the study is used for the approval.

Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

Data sharing details ↗ · clinicaltrials.servier.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Oct 2024, 11 months.

Results were first posted in Dec 2025, 1 year 2 months after primary completion.

Of 173 phase 2 interventional studies under Cholangiocarcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2023
First posted
Oct 13, 2023
StartActual
Oct 10, 2023
Primary completionActual
Oct 1, 2024
CompletionEst.
May 2027
Results first posted
Dec 9, 2025
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06081829
Lead sponsor
Servier
Responsible party
Sponsor
First posted
Oct 13, 2023
Start date
Oct 10, 2023
Primary completion
Oct 1, 2024
Completion
May 2027 (estimated)
Results posted
Dec 9, 2025
Last update
Dec 9, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivosidenib

Start the discussion